148 related articles for article (PubMed ID: 26357945)
1. Rapid Control of T3 Thyrotoxicosis in Patients with Metastatic Follicular Thyroid Cancer Treated with Lenvatinib.
Danilovic DL; de Camargo RY; Castro G; Papadia C; Marui S; Hoff AO
Thyroid; 2015 Nov; 25(11):1262-4. PubMed ID: 26357945
[No Abstract] [Full Text] [Related]
2. [Lenvatinib in radioiodine refractory thyroid carcinomas].
de la Fouchardiere C
Bull Cancer; 2016 Nov; 103(11):905-910. PubMed ID: 27817859
[TBL] [Abstract][Full Text] [Related]
3. Lenvatinib induces early tumor shrinkage in patients with advanced thyroid carcinoma.
Masaki C; Sugino K; Saito N; Saito Y; Tanaka T; Ogimi Y; Maeda T; Osaku T; Akaishi J; Hames KY; Tomoda C; Suzuki A; Matsuzu K; Uruno T; Ohkuwa K; Kitagawa W; Nagahama M; Takami H; Ito K
Endocr J; 2017 Aug; 64(8):819-826. PubMed ID: 28659544
[TBL] [Abstract][Full Text] [Related]
4. Factors involved in early lenvatinib dose reduction: a retrospective analysis.
Suyama K; Tomiguchi M; Takeshita T; Sueta A; Yamamoto-Ibusuki M; Shimokawa M; Yamamoto Y; Iwase H
Med Oncol; 2018 Jan; 35(3):19. PubMed ID: 29387983
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Limitations of Lenvatinib Therapy for Radioiodine-Refractory Differentiated Thyroid Cancer: Real-World Experiences.
Masaki C; Sugino K; Saito N; Akaishi J; Hames KY; Tomoda C; Suzuki A; Matsuzu K; Uruno T; Ohkuwa K; Kitagawa W; Nagahama M; Ito K
Thyroid; 2020 Feb; 30(2):214-221. PubMed ID: 31854270
[No Abstract] [Full Text] [Related]
6. Lenvatinib (Lenvima) for thyroid cancer.
Med Lett Drugs Ther; 2015 Aug; 57(1475):e120-1. PubMed ID: 26262885
[No Abstract] [Full Text] [Related]
7. Lenvatinib approved for certain thyroid cancers.
Cancer Discov; 2015 Apr; 5(4):338. PubMed ID: 25720434
[TBL] [Abstract][Full Text] [Related]
8. Lenvatinib improves survival in refractory thyroid cancer.
Mayor S
Lancet Oncol; 2015 Mar; 16(3):e110. PubMed ID: 25683848
[No Abstract] [Full Text] [Related]
9. Case Report: Management of an Elderly Patient With Metastatic Radioiodine-Resistant Differentiated Thyroid Cancer in a Rural Community, Remote From Specialist Oncology Services.
Wybrew R; Loynd M; Wybrew M; Samuel L
Front Endocrinol (Lausanne); 2020; 11():581014. PubMed ID: 33597920
[TBL] [Abstract][Full Text] [Related]
10. Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer.
Iñiguez-Ariza NM; Ryder MM; Hilger CR; Bible KC
Thyroid; 2017 Jul; 27(7):923-927. PubMed ID: 28471306
[TBL] [Abstract][Full Text] [Related]
11. Lenvatinib receives approval in DTC.
J Nucl Med; 2015 Apr; 56(4):12N. PubMed ID: 25834176
[No Abstract] [Full Text] [Related]
12. Lenvatinib in differentiated thyroid carcinoma: the Italian experience.
Piovesan A
Future Oncol; 2019 Aug; 15(24s):1-2. PubMed ID: 31385528
[No Abstract] [Full Text] [Related]
13. FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine-Refractory Differentiated Thyroid Cancer.
Nair A; Lemery SJ; Yang J; Marathe A; Zhao L; Zhao H; Jiang X; He K; Ladouceur G; Mitra AK; Zhou L; Fox E; Aungst S; Helms W; Keegan P; Pazdur R
Clin Cancer Res; 2015 Dec; 21(23):5205-8. PubMed ID: 26324740
[TBL] [Abstract][Full Text] [Related]
14. [Preclinical and clinical researches of lenvatinib mesylate (Lenvima capsule), a novel antitumor agent approved for thyroid cancer treatment].
Tsuruoka A; Matsui J; Suzuki T; Koyama N; Watanabe T; Funahashi Y
Nihon Yakurigaku Zasshi; 2015 Nov; 146(5):283-90. PubMed ID: 26558314
[No Abstract] [Full Text] [Related]
15. Lenvatinib-Induced Acute Pancreatitis Associated With a Pancreatic Pseudocyst and Splenic Pseudoaneurysms.
Kawakami H; Kubota Y; Ban T; Shibata N; Hosokawa A
Pancreas; 2018 Jul; 47(6):e34-e35. PubMed ID: 29894425
[No Abstract] [Full Text] [Related]
16. A novel heat shock protein inhibitor KU757 with efficacy in lenvatinib-resistant follicular thyroid cancer cells overcomes up-regulated glycolysis in drug-resistant cells in vitro.
Subramanian C; Gorney R; Wang T; Ge D; Zhang N; Zuo A; Blagg BSJ; Cohen MS
Surgery; 2021 Jan; 169(1):34-42. PubMed ID: 32718802
[TBL] [Abstract][Full Text] [Related]
17. Lenvatinib - A multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer.
Hewett Y; Ghimire S; Farooqi B; Shah BK
J Oncol Pharm Pract; 2018 Jan; 24(1):28-32. PubMed ID: 27856921
[TBL] [Abstract][Full Text] [Related]
18. [Medical Assistance Based on Interviews Conducted before Physician Examination by a Pharmacist for Outpatients with Thyroid Cancer Treated with Lenvatinib].
Kawachi Y; Kimura M; Go M; Ohnishi M; Yoshimura T
Gan To Kagaku Ryoho; 2017 Jun; 44(6):507-511. PubMed ID: 28698443
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy and Safety of Lenvatinib for Unresectable Anaplastic Thyroid Cancer].
Yamazaki H; Shimizu S; Iwasaki H; Yoshida T; Suganuma N; Yamanaka T; Kojima I; Masudo K; Toda S; Nakayama H; Masuda M
Gan To Kagaku Ryoho; 2017 Aug; 44(8):695-697. PubMed ID: 28860443
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine kinase inhibitors in iodine-refractory differentiated thyroid cancer: experience in clinical practice.
Molina-Vega M; García-Alemán J; Sebastián-Ochoa A; Mancha-Doblas I; Trigo-Pérez JM; Tinahones-Madueño F
Endocrine; 2018 Feb; 59(2):395-401. PubMed ID: 29275532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
